ZIM Laboratories Limited (ZIM) today announced that it has filed the regulatory dossier for approval of Rizatriptan orally dissolving film in Europe.
Rizatriptan orally dissolving film is a product developed using our Thinoral® technology which yields instantly wettable, rapidly dissolving, and stable films. The product is used in the treatment of migraine which is invariably associated with symptoms like nausea and vomiting. The fast dissolving feature provides faster onset of action, and the flexible nature of film dosage form allows for convenience in carrying. As the presently available comparable product in the market is a mouth dissolving tablet which is extremely fragile, ZIM's product offering is likely to provide significant advantage to patients in portability as well as faster action.
"The submission of the Rizatriptan orally dissolving film MAA represents a critical milestone for ZIM and for European patients suffering from Migraine. This submission puts us one step closer to creating a portfolio of various therapeutic products that target patient convenience and treatment adherence for special need population." said Dr. Anwar Daud, Managing Director of ZIM Laboratories Limited. "Securing a regulatory approval for our Thinoral® technology based products in Europe will be an important step in our overall commercialization strategy for this technology. And positioning ZIM as an important player in the complex generics sphere."
Shares of Zim Laboratories Ltd was last trading in BSE at Rs.67 as compared to the previous close of Rs. 67.5. The total number of shares traded during the day was 565 in over 23 trades.
The stock hit an intraday high of Rs. 69.25 and intraday low of 66.25. The net turnover during the day was Rs. 37891.